The results from the clinical validation cohort were consistent with these previous analyses.<h4>Conclusions</h4>Our findings suggest that the m6A modification influences the tumor microenvironment and that IGF2BP1 acts as an independent predictor of immunotherapy response in LUAD. This evidence concerns the gene IGF2BP1 and neoplasm.